With its strong R&D capabilities, Conjupro continues to invest in research and development to enrich the product pipeline. Primarily, our focus is to develop innovative medicines in the following areas:

• Oncology
• Neurology
• Cardio-cerebrovascular

Conjupro adheres to ICH / GCP guidelines to conduct clinical research and the international quality standards set forth by our parent company, CSPC for all other business.